Novel therapy approach in primary stroke prevention: Simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival

Neurological Research

Volumn 33, Issue 2, 2011, Pages 201-207

  Wengenmayer, Christina ^a   Krikov, Maxim ^a   Mueller, Susanne ^b   Lucht, Kristin ^a   Villringer, Arno ^c   Hocher, Berthold ^a,d   Unger, Thomas ^a   Thoene Reineke, Christa ^b  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MPI für Kognitions und Neurowissenschaften   (Germany)

^d UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Endothelin; Hypertension; Natriuretic peptides; Stroke

Indexed keywords

ALBUMIN; BIG ENDOTHELIN 1; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CREATININE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; POTASSIUM; SLV 338; UNCLASSIFIED DRUG; UREA;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY WEIGHT; BRAIN INFARCTION SIZE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERANCE; FLUID INTAKE; FOOD INTAKE; HIGH SODIUM INTAKE; INCIDENCE; MALE; MORTALITY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM BLOOD LEVEL; PRIMARY PREVENTION; RAT; STROKE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT RESPONSE; UREA BLOOD LEVEL; URINALYSIS; URINE VOLUME;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; HYPERTENSION; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN; NEUROPROTECTIVE AGENTS; PROTEASE INHIBITORS; RATS; RATS, INBRED SHR; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79951893913     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164111X12881719352534     Document Type: Article

References (36)

1. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008;55:310-8.
2. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive Rats (SHR). Circ Res 1974;34/35:143-53.
3. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-7. (Pubitemid 29453643)
4. Davenport AP, Battistini B. Classification of endothelin receptors and antagonists in clinical development. Clin Sci (Lond) 2002;103(Suppl 48):1S-3S.
5. Estrada V, Tellez MJ, Moya J, Fernández-Durango R, Egido J, Fernández Cruz AF. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke. Am J Hypertens 1994;7:1085-9.
6. Barone FC, White RF, Elliott JD, Feuerstein GZ, Ohlstein EH. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol 1995;26(Suppl 3):S404-7.
7. Lehmberg J, Putz C, Furst M, Beck J, Baethmann A, Uhl E. Impact of the endothelin-A receptor antagonist BQ 610 on microcirculation in global cerebral ischemia and reperfusion. Brain Res 2003;961:277-86. (Pubitemid 36071589)
8. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008;21:733-41. (Pubitemid 351913612)
9. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003;41:383-9.
10. Akdemir G, Luer MS, Dujovny M, Misra M. Intraventricular atrial natriuretic peptide for acute intracranial hypertension. Neurol Res 1997;19:515-20.
11. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7:943-7. (Pubitemid 24372788)
12. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond) 1996;91:283-91. (Pubitemid 26305918)
13. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993;73:375-411.
14. Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 2004;94:237-9. (Pubitemid 38902881)
15. Thone-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormählen D, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol 2004;44(Suppl 1):S76-9.
16. Thone-Reineke C, Olivier J, Godes M, Zart R, George I, Bauer C, et al. Effects of angiotensin-converting enzyme inhibition and calcium channel blockade on cardiac apoptosis in rats with 2K1C (two-kidney/one-clip) renovascular hypertension. Clin Sci (Lond) 2003;104:79-85. (Pubitemid 36249926)
17. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995;26:627-34.
18. Xu J, Scholz A, Rosch N, Blume A, Unger T, Kreutz R, et al. Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. J Hypertens 2005;23:2277-85. (Pubitemid 41666758)
19. Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, et al. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension 1999;33:137-44. (Pubitemid 29061854)
20. Touyz RM, Turgeon A, Schiffrin EL. Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2000;36:S300-4.
21. Gries J, Kretzschmar R, Neumann BW. Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs. J Cardiovasc Pharmacol 1989;13(Suppl 4):S79-82.
22. Mies G, Hermann D, Ganten U, Hossmann KA. Hemodynamics and metabolism in stroke-prone spontaneously hypertensive rats before manifestation of brain infarcts. J Cereb Blood Flow Metab 1999;19:1238-46. (Pubitemid 30176452)
23. Tagami M, Kubota A, Nara Y, Yamori Y. Detailed disease processes of cerebral pericytes and astrocytes in stroke-prone SHR. Clin Exp Hypertens A 1991;13:1069-75.
24. Volpe M, Iaccarino G, Vecchione C, Rizzoni D, Russo R, Rubattu S, et al. Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. J Clin Invest 1996;98:256-61. (Pubitemid 26255721)
25. Barone FC, Ohlstein EH, Hunter AJ, Campbell CA, Hadingham SH, Parsons AA, et al. Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat. J Cardiovasc Pharmacol 2000;36:S357-61.
26. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-9. (Pubitemid 27142776)
27. Sironi L, Guerrini U, Tremoli E, Miller I, Gelosa P, Lascialfari A, et al. Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach. J Neurosci Res 2004;78:115-22. (Pubitemid 39305160)
28. Lee JM, Zhai G, Liu Q, Gonzales ER, Yin K, Yan P, et al. Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. Stroke 2007;38:3289-91. (Pubitemid 350175751)
29. Matsuo Y, Mihara S, Ninomiya M, Fujimoto M. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 2001;32:2143-8. (Pubitemid 32868114)
30. Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I, et al. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin- 1 in dogs and rats. Pharmacol Toxicol 2003;92:21-6. (Pubitemid 36238073)
31. ClinicalTrials.gov. To determine the effects of avosentan on doubling of serum creatinine, end stage renal disease and death in diabetic nephropathy. Basel: Speedel Pharma Ltd; 2008.
32. Ovbiagele B. Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch Neurol 2008;65:934-8. (Pubitemid 352008478)
33. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008;52:452-9.
34. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202. (Pubitemid 40179960)
35. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
36. O'Connell JE, Jardine AG, Davidson G, Connell JM. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992;10:271-7.